GlaxoSmithKline Seeking Triple Therapy For Emphysema
September 19, 2012 By zintro Leave a Comment
GlaxoSmithKline Plc is exploring new treatments to replace Advair, the world’s best-selling drug for emphysema and chronic bronchitis caused by smoking. The company is considering a three-in-one treatment delivered in a single device, which would mix an inhaled corticosteroid with MABA, Glaxo’s experimental drug with two modes of action, to reduce inflammation and help open [...]